Maintenance Therapy of Facial Seborrheic Dermatitis with 0.1% Tacrolimus Ointment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hye One | - |
dc.contributor.author | Yang, Yoon Seok | - |
dc.contributor.author | Ko, Hyun Chang | - |
dc.contributor.author | Kim, Gyung Moon | - |
dc.contributor.author | Cho, Sang Hyun | - |
dc.contributor.author | Seo, Young Joon | - |
dc.contributor.author | Son, Sang Wook | - |
dc.contributor.author | Lee, Jong Rok | - |
dc.contributor.author | Lee, Joong Sun | - |
dc.contributor.author | Chang, Sung Eun | - |
dc.contributor.author | Che, Jae We | - |
dc.contributor.author | Park, Chun Wook | - |
dc.date.accessioned | 2021-09-04T12:12:31Z | - |
dc.date.available | 2021-09-04T12:12:31Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2015-10 | - |
dc.identifier.issn | 1013-9087 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/92412 | - |
dc.description.abstract | Background: Topical calcineurin inhibitors (TCIs) have been successfully used to treat seborrheic dermatitis (SD) patients. Meanwhile, treatment of atopic dermatitis (AD) with low-dose, intermittent TCI has been proved to reduce disease flare-ups. This regimen is known as a maintenance treatment. Objective: The aim of this trial was. to investigate the efficacy and tolerability of a maintenance treatment with tacrolimus ointment in patients with facial SD. Methods: During the initial stabilization period, patients with facial SD or AD applied 0.1% tacrolim us ointment twice daily for up to 4 weeks. Clinical measurements were evaluated on either in the whole face or on separate facial regions. When an investigator global assessment score 1 was achieved, the patient applied tacrolimus twice weekly for 20 weeks. We also compared our results with recent published data of placebo controlled study to allow an estimation of the placebo effect. Results: The time to the first relapse during phase II was similar in both groups otherwise significantly longer than the placebo group. The recurrence-free curves of two groups were not significantly different from each other; otherwise the curve of the placebo group was significantly different. There were no significant differences between the 2 groups in the number of DEs, and treatment days for disease exacerbations (DEs). The adverse event profile was also similar between the 2 groups. During the 20 weeks of treatment, the study population tolerated tacrolimus ointment well. Conclusion: The results of this study suggest that maintenance treatment with tacrolim us may be, effective in preventing the occurrence of facial SD exacerbations. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN DERMATOLOGICAL ASSOC | - |
dc.subject | PIMECROLIMUS CREAM 1-PERCENT | - |
dc.subject | TOPICAL CALCINEURIN INHIBITORS | - |
dc.subject | ATOPIC-DERMATITIS | - |
dc.subject | PROACTIVE TREATMENT | - |
dc.subject | MALASSEZIA | - |
dc.subject | MODERATE | - |
dc.subject | DISEASE | - |
dc.subject | CORTICOSTEROIDS | - |
dc.subject | 0.03-PERCENT | - |
dc.subject | METAANALYSIS | - |
dc.title | Maintenance Therapy of Facial Seborrheic Dermatitis with 0.1% Tacrolimus Ointment | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Son, Sang Wook | - |
dc.identifier.doi | 10.5021/ad.2015.27.5.523 | - |
dc.identifier.scopusid | 2-s2.0-84943795524 | - |
dc.identifier.wosid | 000363832800006 | - |
dc.identifier.bibliographicCitation | ANNALS OF DERMATOLOGY, v.27, no.5, pp.523 - 530 | - |
dc.relation.isPartOf | ANNALS OF DERMATOLOGY | - |
dc.citation.title | ANNALS OF DERMATOLOGY | - |
dc.citation.volume | 27 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 523 | - |
dc.citation.endPage | 530 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002037715 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordPlus | PIMECROLIMUS CREAM 1-PERCENT | - |
dc.subject.keywordPlus | TOPICAL CALCINEURIN INHIBITORS | - |
dc.subject.keywordPlus | ATOPIC-DERMATITIS | - |
dc.subject.keywordPlus | PROACTIVE TREATMENT | - |
dc.subject.keywordPlus | MALASSEZIA | - |
dc.subject.keywordPlus | MODERATE | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | CORTICOSTEROIDS | - |
dc.subject.keywordPlus | 0.03-PERCENT | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordAuthor | Maintenance therapy | - |
dc.subject.keywordAuthor | Seborrheic dermatitis | - |
dc.subject.keywordAuthor | Tacrolimus ointment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.